MetaVia secures IP for DA‑1726 dual GLP‑1/glucagon oxyntomodulin, protections through 2041

MetaVia tightens IP protection around long‑acting oxyntomodulin candidate DA‑1726

MetaVia Inc. secures an exclusive global intellectual property portfolio that it says underpins commercialization and development of DA‑1726, a once‑weekly subcutaneous oxyntomodulin analogue that acts as a dual GLP‑1 and glucagon receptor agonist. The company announces 39 granted and pending U.S. and international patents licensed from Dong‑A ST Co., Ltd., covering the peptide sequence, formulation and therapeutic design for use as a dual‑incretin therapy in obesity, cardiometabolic diseases and Metabolic Dysfunction‑Associated Steatohepatitis (MASH). Patents presently protect the asset into 2041, with the firm seeking potential term extensions.

MetaVia frames the portfolio as a core asset for advancing DA‑1726 beyond clinical proof‑of‑concept into later‑stage development, saying the claims are structured to defend the molecule, its uses and commercialization pathways. The company highlights that the intellectual property spans structure and method‑of‑use claims that align with its development plan and expected regulatory timelines. CEO Hyung Heon Kim underscores confidence in the patent foundation while pursuing accelerated clinical strategies intended to demonstrate tolerability and differentiated benefit.

Alongside the IP announcement, MetaVia reiterates clinical and preclinical data supporting DA‑1726’s profile. In clinical testing at a 48 mg dose the candidate produces roughly 9% mean weight loss, significant reductions in waist circumference, improved glycemic control and early indicators of direct liver benefit, all with a favorable safety signal. Preclinical mouse studies show greater weight loss versus semaglutide, and the company is advancing titration regimens designed to reach 48 mg and 64 mg in 16 weeks to test whether faster escalation yields advantages over slower GLP‑1 schedules, with results expected in the fourth quarter of 2026.

Mechanistically, MetaVia emphasizes DA‑1726’s combined appetite suppression and increased energy expenditure as a rationale for selecting an oxyntomodulin analogue with dual GLP‑1/GCGR activity. The company positions that pharmacology and the breadth of its patent claims to support multiple therapeutic uses across obesity, metabolic disease and MASH, areas receiving intense clinical and commercial focus.

MetaVia presents the new IP and clinical plan as strategic in a fast‑growing cardiometabolic field, aiming to secure market access and defend development pathways as it moves toward larger safety and efficacy trials. The firm notes the licensed nature of the portfolio from Dong‑A ST and continues to explore patent term extensions beyond the current 2041 horizon.